The company has received European Commission marketing authorization for its new drug, Lenivia (izenivetmab), for reducing pain from osteoarthritis in dogs. This represents a significant regulatory milestone and potential new revenue stream in the European market. However, a Stifel analyst recently lowered the firm's price target on the company from 140 to 130 and maintained a Hold rating on the shares, citing an aggressive 2026 revenue outlook. The stock is currently trailing the broader Dow Jones index.